The tweet was deleted by the author.
But we saved everything 🙂.
Allogene Therapeutics has introduced ALLO-329, an investigational allogeneic CAR-T therapy developed to transform treatment options for autoimmune diseases.
Powered by Dagger technology, the therapy aims to minimize or eliminate the need for lymphodepletion, a common step in traditional cell therapy protocols. ALLO-329 represents a potential breakthrough in cell therapy by seeking a safer and more accessible solution for patients with autoimmune conditions. Further research and clinical validation will be required before the treatment can move toward wider adoption.
View post on X Loading...
The introduction of ALLO-329 not only builds on Allogene Therapeutics’ momentum in advancing CAR-T therapies, but also reaffirms emerging hope for severe autoimmune disease patients, a theme explored in the discussion of a potential breakthrough for patients with critical unmet needs. Further context on the innovative role of Dagger technology in transforming autoimmune disease care can be found through the lens of ALLO-329’s development and strategic direction.